Tong Zi

957 total citations · 1 hit paper
21 papers, 617 citations indexed

About

Tong Zi is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Tong Zi has authored 21 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Tong Zi's work include Extracellular vesicles in disease (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and interferon and immune responses (3 papers). Tong Zi is often cited by papers focused on Extracellular vesicles in disease (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and interferon and immune responses (3 papers). Tong Zi collaborates with scholars based in United States, China and Canada. Tong Zi's co-authors include Jun Nie, Ruixue Yin, Dongzhi Yang, Su Chul Jang, Kyriakos D. Economides, Sriram Sathyanarayanan, Kevin Dooley, Karl Schmidt, Shil Patel and Chang Ling Sia and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Biotechnology and PLoS ONE.

In The Last Decade

Tong Zi

20 papers receiving 593 citations

Hit Papers

Exosome-mediated genetic reprogramming of tumor-associate... 2022 2026 2023 2024 2022 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tong Zi United States 11 361 167 138 117 95 21 617
Guangchao Xu China 15 359 1.0× 126 0.8× 128 0.9× 229 2.0× 90 0.9× 39 750
Margit M. Janát‐Amsbury United States 16 365 1.0× 80 0.5× 109 0.8× 184 1.6× 138 1.5× 34 856
Maohua Cai China 15 417 1.2× 133 0.8× 227 1.6× 267 2.3× 142 1.5× 19 854
Zhiguang Fu China 11 419 1.2× 119 0.7× 145 1.1× 97 0.8× 64 0.7× 17 571
Justin E. Fang United States 6 478 1.3× 108 0.6× 64 0.5× 153 1.3× 45 0.5× 11 765
Shuaiqiang Zhang China 9 279 0.8× 111 0.7× 88 0.6× 43 0.4× 167 1.8× 9 634
Diana Whaley United States 14 217 0.6× 121 0.7× 84 0.6× 128 1.1× 37 0.4× 17 755
Ayelet Shabtay‐Orbach Israel 10 138 0.4× 66 0.4× 141 1.0× 173 1.5× 66 0.7× 13 449
Gudrun Dandekar Germany 13 341 0.9× 105 0.6× 150 1.1× 362 3.1× 218 2.3× 31 840

Countries citing papers authored by Tong Zi

Since Specialization
Citations

This map shows the geographic impact of Tong Zi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tong Zi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tong Zi more than expected).

Fields of papers citing papers by Tong Zi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tong Zi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tong Zi. The network helps show where Tong Zi may publish in the future.

Co-authorship network of co-authors of Tong Zi

This figure shows the co-authorship network connecting the top 25 collaborators of Tong Zi. A scholar is included among the top collaborators of Tong Zi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tong Zi. Tong Zi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Shil, Karl Schmidt, Mohammed Farhoud, et al.. (2022). In vivo tracking of [89Zr]Zr-labeled engineered extracellular vesicles by PET reveals organ-specific biodistribution based upon the route of administration. Nuclear Medicine and Biology. 112-113. 20–30. 39 indexed citations
2.
Kamerkar, Sushrut, Charan Leng, Olga Burenkova, et al.. (2022). Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Science Advances. 8(7). eabj7002–eabj7002. 190 indexed citations breakdown →
3.
Knight, Ashley C., Tong Zi, Steven H. Liang, et al.. (2021). In Vitro Evaluation of [3H]CPPC as a Tool Radioligand for CSF-1R. ACS Chemical Neuroscience. 12(6). 998–1006. 24 indexed citations
4.
Kirwin, Katherine, Su Chul Jang, Kevin Dooley, et al.. (2021). 572 Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity. SHILAP Revista de lepidopterología. A601–A601. 3 indexed citations
5.
Kamerkar, Sushrut, Charan Leng, Kelvin Zhang, et al.. (2021). 842 Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC). SHILAP Revista de lepidopterología. A883–A883.
6.
Lewis, Nuruddeen D., Chang Ling Sia, Katherine Kirwin, et al.. (2020). Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. Molecular Cancer Therapeutics. 20(3). 523–534. 79 indexed citations
7.
Burzyn, Dalia, Charan Leng, Olga Burenkova, et al.. (2020). Abstract A50: Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotide-loaded exosomes results in potent single-agent antitumor activity. Cancer Immunology Research. 8(3_Supplement). A50–A50. 4 indexed citations
8.
Lewis, Nuruddeen D., Chang Ling Sia, Katherine Kirwin, et al.. (2020). 709 Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure. SHILAP Revista de lepidopterología. A425.2–A426. 3 indexed citations
11.
Bregar, Amy, Amit Deshpande, Tong Zi, et al.. (2017). Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecologic Oncology. 145(3). 446–452. 50 indexed citations
12.
Michaelson, Jennifer S., Christopher J. Harvey, Kutlu G. Elpek, et al.. (2017). Abstract SY03-02: Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial. Cancer Research. 77(13_Supplement). SY03–2. 2 indexed citations
13.
Zhou, Yinghui, William M. Rideout, Sireesha Yalavarthi, et al.. (2014). Spontaneous Genomic Alterations in a Chimeric Model of Colorectal Cancer Enable Metastasis and Guide Effective Combinatorial Therapy. PLoS ONE. 9(8). e105886–e105886. 13 indexed citations
14.
Yin, Ruixue, Tong Zi, Dongzhi Yang, & Jun Nie. (2012). Glucose-responsive insulin delivery microhydrogels from methacrylated dextran/concanavalin A: Preparation and in vitro release study. Carbohydrate Polymers. 89(1). 117–123. 48 indexed citations
15.
Yin, Ruixue, Tong Zi, Dongzhi Yang, & Jun Nie. (2011). Glucose and pH dual-responsive concanavalin A based microhydrogels for insulin delivery. International Journal of Biological Macromolecules. 49(5). 1137–1142. 53 indexed citations
16.
Yin, Ruixue, Tong Zi, Dongzhi Yang, & Jun Nie. (2011). Glucose-responsive microhydrogels based on methacrylate modified dextran/concanavalin A for insulin delivery. Journal of Controlled Release. 152. e163–e165. 15 indexed citations
17.
Wang, Kemin, Ruixue Yin, Tong Zi, Qiang Yu, & Jun Nie. (2011). Synthesis and characterization of water-soluble glucosyloxyethyl acrylate modified chitosan. International Journal of Biological Macromolecules. 48(5). 753–757. 16 indexed citations
18.
Zhou, Yinghui, William M. Rideout, Tong Zi, et al.. (2009). Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas. Nature Biotechnology. 28(1). 71–78. 59 indexed citations
19.
Zi, Tong, William M. Rideout, M. Isabel Chiu, et al.. (2009). Abstract A22: Response to the triple VEGFR inhibitor tivozanib (AV-951) in KRAS and EGFR driven lung tumors developed in chimeric mouse models. Molecular Cancer Therapeutics. 8(12_Supplement). A22–A22. 1 indexed citations
20.
Farlow, Samuel J., Tong Zi, Xiao‐Jian Sun, et al.. (2009). Abstract A12: Variation in response to triple VEGFR inhibitor tivozanib in mouse models of hepatocellular carcinoma. Molecular Cancer Therapeutics. 8(12_Supplement). A12–A12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026